Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience.
Clostridioides difficile
bezlotoxumab
recurrence
treatment
Journal
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
ISSN: 1988-9518
Titre abrégé: Rev Esp Quimioter
Pays: Spain
ID NLM: 9108821
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
pubmed:
15
3
2022
medline:
28
5
2022
entrez:
14
3
2022
Statut:
ppublish
Résumé
Following the approval of bezlotoxumab in 2017, studies evaluating its effectiveness in prevention of Clostridioides difficile infection under "real-life" conditions are scarce. We conducted a retrospective study developed in a large tertiary care hospital describing the use and outcomes of patients with Clostridioides difficile infection (CDI) treated with bezlotoxumab. A total of 16 patients were include, all of whom had an episode of CDI with high probability of recurrence and 14 of them had some kind of immunosuppression. Bezlotoxumab was effective in the prevention of CDI recurrence in 11 of the 14 cases in which follow up was possible, without significant side effects. Bezlotoxumab was well tolerated and the incidence of recurrent CDI in a high-risk population for recurrence was only 21.4%.
Identifiants
pubmed: 35279984
doi: 10.37201/req/120.2021
pmc: PMC9134882
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Antibodies, Monoclonal
0
Broadly Neutralizing Antibodies
0
bezlotoxumab
4H5YMK1H2E
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
279-283Informations de copyright
©The Author 2022. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).
Références
Eur J Clin Microbiol Infect Dis. 2019 Oct;38(10):1947-1952
pubmed: 31359254
Ann Gastroenterol. 2019 Jan-Feb;32(1):30-38
pubmed: 30598589
J Pediatr Gastroenterol Nutr. 2019 Mar;68(3):343-347
pubmed: 30320666
Infect Dis Ther. 2019 Mar;8(1):87-103
pubmed: 30659481
BMC Vet Res. 2019 Jan 7;15(1):11
pubmed: 30616615
J Clin Med Res. 2019 Jul;11(7):465-471
pubmed: 31236163
Rev Esp Quimioter. 2020 Apr;33(2):151-175
pubmed: 32080996
Am J Gastroenterol. 2002 Jul;97(7):1769-75
pubmed: 12135033
Rev Esp Quimioter. 2019 Apr;32(2):205-207
pubmed: 30847461
Open Forum Infect Dis. 2020 Mar 19;7(4):ofaa097
pubmed: 32363211
J Clin Med Res. 2019 Jan;11(1):1-6
pubmed: 30627271
N Engl J Med. 2017 Jan 26;376(4):305-317
pubmed: 28121498
Clin Microbiol Infect. 2014 Mar;20 Suppl 2:1-26
pubmed: 24118601
Inflamm Bowel Dis. 2019 May 4;25(6):969-979
pubmed: 30852592
Expert Rev Anti Infect Ther. 2016 Sep;14(9):801-8
pubmed: 27462827
J Antimicrob Chemother. 2016 May;71(5):1380-5
pubmed: 26869691
Clin Infect Dis. 2012 Aug;55 Suppl 2:S154-61
pubmed: 22752865
N Engl J Med. 2013 Jan 31;368(5):407-15
pubmed: 23323867
Infect Control Hosp Epidemiol. 2019 Jan;40(1):65-71
pubmed: 30409240
J Dig Dis. 2019 Jun;20(6):301-307
pubmed: 30969003
Aliment Pharmacol Ther. 2015 May;41(9):835-43
pubmed: 25728808
Gastroenterology. 2009 Apr;136(4):1206-14
pubmed: 19162027